Effective April 15, patients may bring one visitor to an appointment.
Learn more about this and other COVID-19 related updates

Clinical Trials & Research

PH3 AMG 510 vs Doce a/mNSCLC

20190009: A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects with Mutated KRAS p.G12C

Disease Types: Lung (Non Small Cell),&nbs

Available at: {clinical_trial_location backspace="7"}PH3 AMG 510 vs Doce a/mNSCLC, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}

{clinical_trial_description}